Subjective cognitive decline in perimenopause
Conditions
Interventions
Healthy control group:None
Perimenopausal SCD group:None
Sponsors
the Affiliated Hospital of Guizhou Medical University
Eligibility
Sex/Gender
Female
Age
50 Years to 55 Years
Inclusion criteria
Inclusion criteria: (1) Perimenopausal women who are in the early (-2) to early (+1a) menopausal transition period according to the Stages of Reproductive Aging +10 (STRAW+10). Early menopausal transition is marked by an increase in menstrual cycle length variability, which is defined as a persistent change in the difference between consecutive cycle lengths of 7 days or more. Persistence is defined as recurrence within 10 cycles after the first occurrence of cycle length variation. Late menopausal transition (-1 stage) Late menopausal transition is marked by the presence of menopause of 60 d or more. The +1a stage of early late menopause is 1 year after the final menstrual period (FMP), which corresponds to the end of perimenopause. Subjects must be able to give informed consent and comply with and complete the study procedures. Subjects were required to complete: 1) Self-Depression Scale (SDS); 2) Memory: Auditory Word Learning Test (AVLT-H); 3) Executive Function: Shape Shifting Tests A & B (STT-A&B) and Montreal Cognitive Assessment (MoCA); 4) Functional Activities Questionnaire (FAQ); and 5) Clinical Dementia Rating (CDR), with normal scores on all of the above scales. and the scores of the above scales are within normal values. (4) Secondary school education or above. ? Age (50-55 years old). (6) BMI (18.5-23.9 kg/m2 ). ?No hormone therapy.
Exclusion criteria
Exclusion criteria: ? Other conditions that may impair cognition or confound assessment: 1) Common brain disorders including neurodegenerative disorders such as Alzheimer's disease, Parkinson's disease, cerebrovascular disease, inflammatory encephalopathies, and head trauma. 2) Serious primary conditions such as severe cardiovascular (myocardial infarction, unstable angina, hospitalization for congestive heart failure, bypass surgery or angioplasty (coronary or carotid artery) transient ischemic attack).3) History of malignancy, carbon monoxide poisoning, and general anesthesia as suggested by current or medical history. ? Patients with neuropsychiatric dysfunction (e.g., dementia, Parkinson's disease, cerebrovascular disease, depressive disorders, mania, mild cognitive dysfunction, etc.). ?People who use medications to treat neurological conditions, such as antidepressants. (iv) Other diseases related to cognition include metabolic diseases, endocrine diseases (e.g., thyroid dysfunction), hypertension, heart disease, anemia, liver disease, kidney disease, infectious diseases, nutritional deficiencies, and diabetes mellitus. ? Those who have never given birth. ? Alcoholics and drug addicts.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| messenger RNA(mRNA);miRNA;Long non-coding RNA(lncRNA);circRNA;BMI;nation;habit; | — |
Secondary
| Measure | Time frame |
|---|---|
| age;hypertension;pregnancy and childbirth;sex hormone test;liver and kidney function;blood lipid;thyroid function;gynecological ultrasound;breast ultrasound;Cervical Vascular Ultrasound;thyroid ultrasound;bone density; | — |
Countries
China
Contacts
Public ContactLin Yang
the Affiliated Hospital of Guizhou Medical University
Outcome results
None listed